Oxybutynin Chloride, Extended-Release Tablets USP, 10 mg, 100 Tablet, Rx Only, Distributed by: Lannett Company, Inc, Philadelphia, PA 19154 NDC: 62175-271-37

FDA recall notice · announced March 20, 2019 · Lannett

Class III FDA/FSIS Class III: use is not likely to cause adverse health consequences.

The product

Oxybutynin Chloride, Extended-Release Tablets USP, 10 mg, 100 Tablet, Rx Only, Distributed by: Lannett Company, Inc, Philadelphia, PA 19154 NDC: 62175-271-37

Reason for recall

Failed Dissolution Specifications

Notes

Distribution: Nationwide, including Puerto Rico.
Lot/code information: Lots: 18226783A, exp 07/2021 and 18232540A, exp 08/2021
Quantity: 14,448 bottles
Status: Terminated
Products in this recall event:
- Oxybutynin Chloride, Extended-Release Tablets USP, 10 mg, 100 Tablet, Rx Only, Distributed by: Lannett Company, Inc, Philadelphia, PA 19154 NDC: 62175-271-37 (D-0996-2019)

Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.